RegenOMedix™ Receives IRB Approval for Clinical Use of Ascellos™ Stem Cells and Therapeutic Exosomes in Pain Management, Orthopedic Care, and Wound Healing
Approval supports structured research and protocol-based physician participation in regenerative clinical applications, empowering you to be at the forefront of innovative therapies.
Boca Raton, FL – February 6, 2026 — RegenOMedix™ announced today that it has received Institutional Review Board (IRB) approval, establishing a credible foundation for clinical research on exosomes in pain, orthopedic care, and wound healing. This milestone advances structured regenerative research and supports ongoing data collection under clinical oversight. Products approved for the study include both Stem Cells and Exosomes that are compliant with the Florida Stem Cell Law.
The IRB approval provides a clear, compliant pathway for licensed physicians, with RegenOMedix™ supporting your efforts through defined protocols and ethical oversight, ensuring you have the support you need in your clinical research.
“This IRB approval creates a foundation for responsibly studying Stem Cells and Exosomes in a clinical environment,” said Bruce Bertman, of RegenOMedix. “It allows physicians to contribute meaningfully to research initiatives that explore how Stem Cells and Exosomes may be applied in areas of high therapeutic interest. We will use a dedicated portal for patient tracking at ClinicalStudyResearch.com.”
The IRB approval pertains solely to clinical study oversight, protocol adherence, and data collection activities. It does not imply FDA approval or marketing authorization for therapeutic use, ensuring clarity on regulatory boundaries.
Through this framework, RegenOMedix™ enables structured investigation into biologic approaches for conditions where conventional treatments may be limited or ineffective. Areas of clinical interest include joint and musculoskeletal pain, orthopedic injuries, and chronic or complex wound healing.
Opportunities for Physician Participation
Licensed physicians and medical clinics interested in participating in the IRB-approved clinical program are encouraged to contact RegenOMedix™. Your involvement offers a meaningful way to advance regenerative medicine and contribute to evidence-based care.
About RegenOMedix
RegenOMedix™ promotes next-generation healing through regenerative medical products, integrative treatment options, and advanced regenerative equipment. The company works with international partners to validate and support products designed to complement the body’s natural healing processes. In addition to supplying biologic and FDA-cleared technologies, RegenOMedix™ provides training, marketing support, and implementation guidance to clinics seeking to expand their regenerative offerings.
Media Contact:
Bruce Bertman
Bruce@RegenOMedix.com
561-325-7000
https://RegenOMedix.com/
To learn more about clinical participation, visit https://regenomedix.com/contact-us/
